(CercleFinance.com) – AstraZeneca announces that a phase III trial evaluating Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced or metastatic triple negative breast cancer (TNBC) was inconclusive.
Indeed, the trial did not achieve its primary objectives of improving overall survival compared to paclitaxel with placebo, neither in the overall population nor in a subgroup of patients with specific biomarker alterations (PIK3CA, AKT1 or PTEN).
TNBC is difficult to treat due to the lack of known actionable biomarker targets, and chemotherapy remains the primary treatment.
Despite the disappointing results, these data are important for better understanding this aggressive form of breast cancer, underlines the laboratory which continues its research on Truqap and other treatments as part of its clinical development program.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
